Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 132, Issue 8, Pages 1741-1750
Publisher
Wiley
Online
2012-09-18
DOI
10.1002/ijc.27851
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias
- (2011) Cui-Hua Ma et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
- (2011) Damien Reynaud et al. CANCER CELL
- Accurate identification of A-to-I RNA editing in human by transcriptome sequencing
- (2011) J. H. Bahn et al. GENOME RESEARCH
- Identification of Widespread Ultra-Edited Human RNAs
- (2011) Shai Carmi et al. PLoS Genetics
- miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts
- (2010) Anna M. Eiring et al. CELL
- Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia
- (2010) Andrea Hoelbl et al. EMBO Molecular Medicine
- Molecular pathways to CML stem cells
- (2010) Kristen N. Rice et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Inosine cyanoethylation identifies A-to-I RNA editing sites in the human transcriptome
- (2010) Masayuki Sakurai et al. Nature Chemical Biology
- Double-stranded RNAs containing multiple IU pairs are sufficient to suppress interferon induction and apoptosis
- (2010) Patrice Vitali et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- RNA editing in human cancer: review
- (2009) JOZEF ŠKARDA et al. APMIS
- PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice
- (2009) C. Peng et al. BLOOD
- Adenosine deamination in human transcripts generates novel microRNA binding sites
- (2009) Glen M. Borchert et al. HUMAN MOLECULAR GENETICS
- Adenosine Deaminase ADAR1 Increases Gene Expression at the Translational Level by Decreasing Protein Kinase PKR-Dependent eIF-2α Phosphorylation
- (2009) Ying Wang et al. JOURNAL OF MOLECULAR BIOLOGY
- Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets
- (2009) J. M. Flanagan et al. MOLECULAR CANCER THERAPEUTICS
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia
- (2009) Yaoyu Chen et al. NATURE GENETICS
- IL-3 and Oncogenic Abl Regulate the Myeloblast Transcriptome by Altering mRNA Stability
- (2009) Jason Ernst et al. PLoS One
- ADAR1 is required for hematopoietic progenitor cell survival via RNA editing
- (2009) R. XuFeng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Requirement of c-Myb for p210BCR/ABL-dependent transformation of hematopoietic progenitors and leukemogenesis
- (2008) M. R. Lidonnici et al. BLOOD
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling
- (2008) Jochen C Hartner et al. NATURE IMMUNOLOGY
- BCR-ABL-transformed GMP as myeloid leukemic stem cells
- (2008) Y. Minami et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started